NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast Cancer

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2013
This randomized, parallel cohort, two stage, double-blind, placebo-controlled study evaluated the oral PI3K inhibitor BKM120 in combination with trastuzumab and paclitaxel in HER2-positive, PIK3CA wild-type and PIK3CA mutant primary breast cancer prior to surgery (neo-adjuvant setting).
Epistemonikos ID: 93b75f0ca8c949f01a3be7ac22643eea64b2f33d
First added on: May 11, 2024